INNO 202

Drug Profile

INNO 202

Latest Information Update: 27 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innogenetics
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interferon gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Septic shock

Most Recent Events

  • 13 Oct 2006 No development reported - Preclinical for Septic shock in Belgium (unspecified route)
  • 20 May 2003 INNO 202 is available for licensing (http://www.innogenetics.com)
  • 20 May 2003 Preclinical data from a media release have been added to the Vascular Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top